In contrast, patients with stage III cancer (n = 151) exhibited a high risk of metastasis regardless of parity status (P > .05, Cox proportional hazards regression for all comparisons), for example, 44 vs 58 metastatic recurrences in ER-positive, nulliparous women vs those with PPBC less than 10 years at 5 years follow-up (eTable 1 in the Supplement). The gene discussed is ESR1; the disease is cancer.